Article

Post-daunorubicin treatment effects on cardiovascular function in the Ts65Dn mouse model of Down syndrome

2026-05-26

Abstract excerpt

<h4>ABSTRACT</h4> Adults with Down syndrome (DS) are two times more likely to be diagnosed with chronic heart failure post-anthracycline chemotherapy compared to age and sex-matched adults without DS. They have an elevated lifetime risk of cardiovascular diseases, increasing their likelihood of anthracycline-induced chronic cardiovascular toxicity. We investigated the chronic effects of daunorubicin on the cardio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 49a5e212-4fc0-54cb-a4ce-18523c7f47ef
DOI: 10.64898/2026.05.21.726916

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Post-daunorubicin treatment effects on cardiovascular function in the Ts65Dn mouse model of Down syndromeDOI 10.64898/2026.05.21.726916Read

Cardiopulmonary structural, functional and immune-alterations in a Down syndrome mouse model and upon modulation of EGCGSemantic proximity Read

Postnatal lethality and cardiac anomalies in the Ts65Dn Down Syndrome mouse modelSemantic proximity Read

Characterization of the cardiac phenotype in neonatal Ts65Dn mice.Semantic proximity Read

Unraveling the Genetic Blueprint of Doxorubicin-Induced Cardiotoxicity Through Systems Genetics ApproachesSemantic proximity Read

Expression of the anthracycline-metabolizing enzyme carbonyl reductase 1 in hearts from donors with Down syndrome.Semantic proximity Read

Desmoplakin Cardiomyopathy: Gene Dose-Dependent Myocardial Remodeling, Arrhythmias, and Premature Death.Semantic proximity Read

Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.Semantic proximity Read

The App-Runx1 region is critical for birth defects and electrocardiographic dysfunctions observed in a Down syndrome mouse model.Semantic proximity Read

Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndromeSemantic proximity Read

Cardiac AAV9:PKP2 Gene Therapy Reduces Ventricular Arrhythmias, Reverses Adverse Remodeling, and Reduces Mortality in a Mouse Model of ARVCSemantic proximity Read

Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome.Semantic proximity Read

Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndromeSemantic proximity Read